Fig. 2
From: RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Overall Survival and Progression Free Survival Stratified by Histology in the Re-RAFFLE Study. The figure provides a comprehensive overview of treatment responses categorized by histological subtypes, highlighting the survival outcomes observed in the context of the Re-RAFFLE study. NSCLC = Non-Small Cell Lung Cancer; CRC = Colorectal Cancer; CUP = Carcinoma of Unknown Primary; OS1 = Overall Survival with first RAF inhibitor; OS2 = Overall Survival with second RAF inhibitor; PFS1 = Progression Free-Survival with first RAF inhibitor; PFS2 = Progression Free-Survival with second RAF inhibitor